Asan Medical Center: Lymphoma trials

The registry lists 13 Lymphoma studies with Asan Medical Center as lead sponsor. 1 are open to participants now and 2 have results posted.

Phase 1 2Phase 2 9Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell LymphomaEnrolling by invitationNCT03383406Phase 2
• Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCLCompletedNCT00379574Phase 1/2Results posted
• Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)CompletedNCT00336583Phase 2Results posted
• Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T CellsCompletedNCT07150468
• Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System LymphomaStatus unknownNCT05083936Not applicable
• Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell LymphomaStatus unknownNCT03399747Phase 2
• Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02753062Phase 2
• R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCLWithdrawnNCT02054559Phase 3
• Abbreviated R-CHOP in Completely Excised Stage I or II DLBCLStatus unknownNCT01279902Phase 2
• Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced CancerCompletedNCT00823524Phase 1/2
• Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other DiseaseCompletedNCT00521430Not applicable
• Gemcitabine for Marginal Zone LymphomaTerminatedNCT00337259Phase 2
• Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's LymphomaCompletedNCT00336843Phase 2